Q1 revenue $156.1M (-30% YoY); net income slumps 90%; guidance raised on adjusted EBITDA

Emergent BioSolutions Inc.

2026-Q1 EPS reported $0.07 revenue$156,100,000

Revenue $156.1M vs $222.2M in Q1 2025; net income $6.8M ($0.07 EPS) vs $68.0M ($1.19 EPS).
Smallpox MCM revenue down 40% to $64.2M; Anthrax MCM down 55% to $21.6M.
Adjusted EBITDA $35.6M (23% margin) vs $79.1M (36% margin) in Q1 2025.
FY 2026 adjusted net income guidance raised to $45-65M (from $25-45M); FY 2026 adjusted EBITDA guidance raised to $155-175M (from $135-155M).
Completed debt refinancing with $150M term loan; secured over $200M in new U.S./Canada government contracts.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Emergent BioSolutions Inc. reported first quarter ended March 31, 2026 results: revenue $156.1 million, net income $6.8 million, EPS $0.07.

Period: first quarter ended March 31, 2026
Revenue: $156.1 million
Net income: $6.8 million
EPS: $0.07
Result: reported results

Exact text from the filing

and is incorporated herein by reference. --- EX-99.1 (EX-99.1) --- EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS • First Quarter 2026 Total Revenues of $156.1 million • First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% • First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG,

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Emergent BioSolutions Inc. reported Q1 2026 results: revenue $156.1, net income $6.8, EPS 0.07.

Period: Q1 2026
Revenue: $156.1
Net income: $6.8
EPS: 0.07
Result: reported results

Exact text from the filing

($ in millions, except per share amounts) Q1 2026 Q1 2025 % Change Total Revenues $ 156.1 $ 222.2 (30) % Net Income $ 6.8 $ 68.0 (90) % Net Income per Diluted Share $ 0.07 $ 1.19 (94) %

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Emergent BioSolutions Inc. reported First Quarter 2026 results: revenue $156.1 million, net income $6.8 million, EPS $0.07.

Period: First Quarter 2026
Revenue: $156.1 million
Net income: $6.8 million
EPS: $0.07
Result: reported results

Exact text from the filing

First Quarter 2026 Total Revenues of $156.1 million • First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% • First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23%

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-26-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.